<DOC>
	<DOCNO>NCT01329562</DOCNO>
	<brief_summary>The purpose study ( 1 ) evaluate pain-free efficacy Treximet™ follow treatment menstrual migraine , ( 2 ) investigate level Calcitonin gene-related peptide ( CGRP ) , estrogen , cortisol , vasoactive intestinal peptide ( VIP ) , alpha ( ) -amylase , Prostaglandin E2 ( PGE2 ) , Prostaglandin I2 ( PGI2 ) beta ( ß ) -endorphin saliva Treximet™ , ( 3 ) evaluate efficacy Treximet™ return baseline level follow treatment , ( 4 ) correlate estrogen saliva vs. urinary estradiol mid-luteal , onset menstrually-related migraine , successful treatment Treximet™ .</brief_summary>
	<brief_title>CGRP , Estrogen , Cortisol , VIP , α-Amylase , PGE2 , PGI2 ß-Endorphin Levels Menstrual Migraine Before After Treximet</brief_title>
	<detailed_description>This double-blind multi-site study conduct enroll 40 evaluable participant . All subject medically stable enrollment stabilize dosage daily medication . At Visit 1 ( Baseline ) follow Informed Consent , physical neurological exam , baseline electrocardiogram ( ECG ) , vital sign complete . A urine pregnancy test collect subject childbearing potential . Routine lab ( electrolyte panel creatinine , alanine aminotransferase ( ALT ) / aspartate aminotransferase ( AST ) , luteinizing hormone ( LH ) lab ( menstrual cycle stag ) baseline saliva sample ( CGRP , estrogen , cortisol , VIP , a-amylase , PGI2 , PGE2 β-endorphin analysis ) collect . Subjects headache-free Visit 1 . A medical , headache , medication history collect subject eligible subject randomize 1:1 Group A Group B . Group A receive Treximet™ ( sumatriptan succinate 85 milligram ( mg ) naproxen sodium 500 mg ) 1 tablet . Group B provide 1 match placebo tablet . Subjects instructed start study medication notify study staff lab result normal eligible proceed . Subjects instruct treat early possible follow onset typical menstrual headache . Groups A B provide Treximet™ 1 tablet rescue 2 24 hour persistent recur headache . Subjects receive Diary instruction Digital Versatile Disc ( DVD ) regard documentation . Migraine associate symptom ( ie nausea , vomiting , light sensitivity , sound sensitivity ) collect well sleeplessness , difficulty think bodily pain , menstrual associate symptom ( include intensity menstrual cramp ) . Subjects give kit write instruction collection urine saliva sample additional saliva instruction DVD . All subject give LH test kit define time ovulation . Diary documentation begin time ovulation . They collect baseline saliva first morning urine sample mid-luteal time period two consecutive day , define 4-7 day LH surge . Subjects also instruct begin collection saliva 48 hour prior start menses 8:00 , 2:00 pm , 8:00 pm two day menstrual migraine occurs . They also collect first morning urine sample two morning prior menses . At point headache onset , subject instruct collect saliva onset pain , time treatment , 2 24 hour follow treatment , pain free , 2 hour pain free , 24 hour pain free . Subjects also instruct collect urine specimen pain free follow treatment study medication . Subjects document migraine associate symptom , menstrual associate symptom , recurrence symptom saliva collection time point provide Diary per instruction . Subjects instruct phone study coordinator end menstrual cycle return Visit 2 within 7 day . _________________________ At Visit 2 ( Review ) Diaries review frozen saliva urine sample return clinic . Subjects must meet follow criterion urine saliva analysis : - Diary review indicate headache would , left untreated , least one symptom migraine ( nausea , vomit , phonophobia , photophobia ) . And - Headache associate onset menses And • Saliva urine sample return clinic . Medical medication history updated adverse event collect . A urine pregnancy test collect subject childbearing potential . Drug accountability compliance assess .</detailed_description>
	<mesh_term>Migraine Disorders</mesh_term>
	<mesh_term>Premenstrual Syndrome</mesh_term>
	<mesh_term>Hydrocortisone</mesh_term>
	<mesh_term>Naproxen</mesh_term>
	<mesh_term>Sumatriptan</mesh_term>
	<mesh_term>Endorphins</mesh_term>
	<mesh_term>Estrogens</mesh_term>
	<mesh_term>Calcitonin Gene-Related Peptide</mesh_term>
	<criteria>Subject 1. female age 1845 , childbearing potential , negative pregnancy test ( urine serum ) screen , agree one following : Complete abstinence intercourse 2 week prior administration investigational product , throughout study , time interval ( 5 day ) completion premature discontinuation study , History bilateral tubal ligation Sterilization male partner ; , Implants levonorgestrel ; , Injectable progestogen ; , Oral contraceptive ( combination therapy ethinyl estradiol plus progestin ) placebo week every 13 month ; , Any intrauterine device ( IUD ) publish data show high expected failure rate le 1 % per year ( IUDs meet criterion ) ; , Spermicide plus mechanical barrier ( e.g. , spermicide plus male condom female diaphragm ) ; , Any barrier method ( use combination acceptable method ) ; , Any method publish data show high expected failure rate method le 1 % per year . 2. formally diagnose International Classification Headache Disorders ( ICHD ) menstrual migraine 3. regular predictable monthly menstrual cycle within range 2232 day past 3 cycle . 4. few 15 headache day per month past 3 month 5. headache , leave untreated , would least 1 symptom migraine ( nausea , vomit , photophobia , phonophobia ) respond triptan ergotaminecontaining medication least 50 % headache 6. history reliably predict menstrual migraine headache onset least 70 % time 7. medically stable determine Investigator 8. take concomitant medication , stabilize dosage discretion investigator 9. able understand communicate intelligibly study observer 10. able take oral medication , adhere medication regimen perform study procedure 11. able read comprehend write instruction willing complete procedure assessment require protocol 12. able demonstrate willingness participate sign understand informed consent full explanation study Subject 1. history serotonin syndrome . 2. medical condition , opinion investigator , could alter response study medication confound result study ( ie . pathology salivary gland viral bacterial sialadenitis obstructive sialadenitis Sjögren 's Syndrome ) 3. childbearing potential use adequate contraceptive measure 4. history retinal , basilar hemiplegic migraine , cluster headache , secondary headache ( due trauma , infection , alteration homeostasis , ear , nose throat ( ENT ) psychiatric disorder , cranial cervical disorder neuralgias ) 5. investigator 's opinion , likely unrecognized cardiovascular cerebrovascular disease ( base history presence risk factor include limited , hypertension , hypercholesterolemia , smoker , obesity , diabetes , family history coronary artery disease ) 6. blood pressure equal great 160/90 millimeter mercury ( mmHg ) 2 3 blood pressure ( BP ) measurement screen take angiotensinconverting enzyme ( ACE ) inhibitor angiotensin receptor blocker 7. history significant congenital heart disease , cardiac arrhythmia require medication , history clinically significant electrocardiogram abnormality , investigator 's opinion , contraindicate participation study 8. evidence history ischemic vascular disease include : ischemic heart disease , ischemic abdominal syndrome , peripheral vascular disease Raynaud 's Syndrome , signs/symptoms consistent 9. evidence history central nervous system pathology include stroke and/or transient ischemic attack ( TIAs ) , epilepsy structural brain lesion lower convulsive threshold ; treat antiepileptic drug seizure control within 5 year prior screen 10. history impair hepatic renal function , investigator 's opinion , contraindicate participation study 11. hypersensitivity , intolerance , contraindication use triptan , nonsteroidal antiinflammatory drug ( NSAID ) aspirin ( include sumatriptan naproxen preparation ) nasal polyps asthma 12. currently take , take previous three month , migraine prophylactic medication contain methysergide ; take migraine menstrual migraine prophylactic medication stabilize ( eg . Perimenstrual use triptans estradiol patch ) 13. recent history regular use opioids barbiturates treatment migraine headache and/or nonmigraine pain medication overuse opinion investigator exacerbate contribute current headache pattern subject . Overuse define average 10 day per month last 6 month . 14. take , plan take , monoamine oxidase inhibitor ( MAOI ) , include herbal preparation contain St. John 's Wort ( Hypericum perforatum ) , anytime within 2 week prior screen 2 week post final study treatment . 15. currently take plan continue oral steroid time screen onset menses treat study medication ( discretion investigator ) 16. history bleed disorder currently take anticoagulant antiplatelet agent . 17. evidence history gastrointestinal surgery gastrointestinal ( GI ) ulceration perforation past six month , gastrointestinal bleeding past year ; evidence history inflammatory bowel disease 18. pregnant , actively try become pregnant , breast feed 19. evidence alcohol substance abuse within last year concurrent medical psychiatric condition , investigator 's judgment , likely interfere study conduct , subject cooperation , evaluation interpretation study result , otherwise contraindicate participation clinical trial . 20. participate investigational drug trial within previous four week plan participate another study time study .</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>March 2014</verification_date>
	<keyword>Menstrual migraine</keyword>
	<keyword>Menstrually-related migraine</keyword>
	<keyword>Treximet</keyword>
	<keyword>CGRP</keyword>
	<keyword>calcitonin gene-related peptide</keyword>
</DOC>